Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy

  • Molecules. 2024 May 2;29(9):2110. doi: 10.3390/molecules29092110.
Domiziana Masci  1 ,  Michela Puxeddu  2 ,  Romano Silvestri  2 ,  Giuseppe La Regina  2
Affiliations
  • 1. Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.
  • 2. Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
PMID: 38731601 DOI: 10.3390/molecules29092110
Abstract

Alterations in cellular metabolism, such as dysregulation in glycolysis, lipid metabolism, and glutaminolysis in response to hypoxic and low-nutrient conditions within the tumor microenvironment, are well-recognized hallmarks of Cancer. Therefore, understanding the interplay between aerobic glycolysis, lipid metabolism, and glutaminolysis is crucial for developing effective metabolism-based therapies for Cancer, particularly in the context of colorectal Cancer (CRC). In this regard, the present review explores the complex field of metabolic reprogramming in tumorigenesis and progression, providing insights into the current landscape of small molecule inhibitors targeting tumorigenic metabolic pathways and their implications for CRC treatment.

Keywords
Warburg effect; cancer; colorectal cancer; glutaminolysis; lactate dehydrogenase; lipid metabolism; metabolism.
Products